Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Byakko-ka-ninzin-to is a traditional Kampo (Japanese herbal) medicine derived from the classical Chinese formula Bai-Hu-Jia-Ren-Shen-Tang. It is a multi-component formulation consisting of five primary medicinal herbs: Gypsum fibrosum (Sekko), Anemarrhena asphodeloides rhizome (Chimo), Glycyrrhiza uralensis root (Kanzou/Licorice), Oryza sativa seed (Kobei/Rice), and Panax ginseng root (Ninjin). In modern clinical practice, particularly in Japan, it is approved for the treatment of conditions characterized by severe thirst and heat, including diabetes mellitus, atopic dermatitis, xerostomia (dry mouth), and heatstroke. Pharmacologically, it is recognized for its anti-inflammatory, anti-pyretic, and potential glucose-modulating properties. Research has indicated that it may influence metabolic pathways by modulating serum glucagon levels, although its therapeutic effects are generally attributed to the synergistic action of its diverse phytochemical constituents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on byakko-ka-ninzin-to.